Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Powershares Db Multi-Sector Commodi Powershares Db Oil Fund
DBO
5
United States Oil Fund LP
USO
No Data
Table: Lotus Pharmaceutical Apr Rev NT$3.09B Vs NT$2.57B
Table: Lotus Pharmaceutical Mar Rev NT$4.35B Vs NT$1.59B
Table: Lotus Pharmaceutical FY Net Profit NT$4.72B Vs NT$5.07B
Yuanta Securities Downgrades Lotus Pharmaceutical to Hold From Buy, Price Target Is NT$260
Table: Lotus Pharmaceutical Feb Rev NT$2.24B Vs NT$966.7M
Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region